Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breaking the Immune Sanctuary: Targeting Metastatic Niches.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Same author

Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.

Journal of surgical oncology·2026

Same author

Improving Adherence to National Guidelines Regarding Neoadjuvant Systemic Therapy in the Management of Breast Cancer: A Single-Institution Quality Improvement Initiative.

European journal of breast health·2026

Same author

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier.

Cell reports·2026

Same author

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

Breast cancer research and treatment·2026

Same author

Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).

Cancer immunology research·2026

Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026

Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026

Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026

Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026

Same journal

Minimally Invasive/Robotic Surgery for Colorectal Liver Metastasis.

Surgical oncology clinics of North America·2026

Same journal

Minimally Invasive / Robotic Surgery for Hepatobiliary Cancer.

Surgical oncology clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 30, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Dendritic Cell-Based Immunotherapy for Solid Tumors.

Camille Baumrucker¹, Theresa Relation², Brian J Czerniecki²

¹Department of Surgery, George Washington University, Washington, DC 20037, USA.

Surgical Oncology Clinics of North America

|March 28, 2026

Summary

This summary is machine-generated.

Dendritic cells (DCs) are crucial for cancer immunity, activating immune cells and directly killing tumors. Ongoing clinical trials explore their potential as immunotherapies across various cancers, showing promise for improved patient survival.

Keywords:

Cancer Dendritic cell Immunotherapy Tumor microenvironment Vaccine

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Mar 30, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Dendritic cells (DCs) bridge innate and adaptive immunity.
DCs modulate the tumor microenvironment by activating immune cells and directly killing tumor cells.

Purpose of the Study:

To review the role and therapeutic potential of dendritic cells (DCs) in cancer immunotherapy.
To highlight ongoing clinical trials and future research directions for DC-based cancer treatments.

Main Methods:

Review of existing literature and clinical trial data on dendritic cell therapies.
Analysis of DC mechanisms in tumor immunology and their clinical applications.

Main Results:

Over 300 clinical trials investigating DCs in cancers like melanoma, breast, prostate, brain, and blood cancers.
Intratumoral DC injection demonstrates direct anti-tumor effects.
Sipuleucel-T, an FDA-approved DC therapy, improves survival in prostate cancer.

Conclusions:

Dendritic cell therapy is a promising avenue for cancer immunotherapy, with ongoing trials exploring various applications.
Combination therapies and targeting early-stage disease are emerging strategies.
Further research is necessary to optimize dendritic cell-based therapeutic approaches.